<DOC>
	<DOCNO>NCT02061085</DOCNO>
	<brief_summary>Multicentre , prospective , non-controlled phase II clinical trial evaluate efficacy tolerability first line single agent Eribulin patient HER2-negative metastatic breast carcinoma previously expose taxanes early stage . The primary objective study determine median time progression achieve Eribulin . Other secondary objective ; overall response rate , clinical benefit rate , time treatment progression , duration response toxicity profile .</brief_summary>
	<brief_title>Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer First Line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically confirm metastatic breast cancer HER2 negative , stage IIIb/IV Previous history early disease ( stage IIIIb ) , surgically resect treated standard chemotherapy least 12 week include taxane ixabepilone Patients must progress 36 month treatment taxanes ixabepilone . Age ≥ 18 year Given write inform consent Index Eastern Cooperative Oncology Group ( ECOG ) 0 1 Patients must recover toxicity relate previous treatment ( CTC ≥ 1 ) Measurable evaluable disease ( RECIST 1.1 ) Adequate bone marrow function Adequate hepatic function Adequate renal function Life expectancy ≥ 3 month Breast cancer patient initially diagnose local disease advance metastatic disease . Patients previously receive cytotoxic therapy Hormone therapy permit patient interrupt least two week start study treatment . Major surgery significant traumatic injury 4 week prior study treatment patient may require major surgery assay . Brain metastases leptomeningeal uncontrolled . Serious medical condition / properly control ( unstable angina , lung function severe impair , uncontrolled diabetes , active serious infection , liver disease , HIV seropositivity , active bleeding diathesis ) Other malignancy last three year , except : cervical carcinoma situ , basal cell carcinoma squamous cell skin carcinoma , properly treat Patients pregnant breastfeeding , adult reproductive capacity wich use effective contraception . Patients receive chronic treatment systemic corticosteroid immunosuppressive drug ( except corticosteroid daily dose equivalent prednisone ≤ 20mg stable dose regimen one minimum 4 week prior study entry . Topical inhale corticosteroid allow Active alcoholism drug addiction document . Prior history noncompliance medical regimen Patients want comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Breast Neoplasm Metastasis</keyword>
	<keyword>Receptor , HER-2</keyword>
	<keyword>Eribulin</keyword>
	<keyword>Furans , quetones</keyword>
	<keyword>Antimitotic agent</keyword>
</DOC>